These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17373903)

  • 1. Biological therapies: new treatment options for ANCA-associated vasculitis?
    Aries PM; Lamprecht P; Gross WL
    Expert Opin Biol Ther; 2007 Apr; 7(4):521-33. PubMed ID: 17373903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Are anti-TNFAb indicated in systemic necrotizing vasculitides?].
    Guillevin L
    Rev Med Interne; 2005 Oct; 26(10):769-70. PubMed ID: 16039017
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vasculitis management: discovery of antineutrophil cytoplasmic antibodies (ANCA)].
    Guillevin L
    Presse Med; 2007 May; 36(5 Pt 2):843-4. PubMed ID: 17449373
    [No Abstract]   [Full Text] [Related]  

  • 5. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.
    Huugen D; Tervaert JW; Heeringa P
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1100-7. PubMed ID: 17699331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.
    Roccatello D; Baldovino S; Alpa M; Rossi D; Napoli F; Naretto C; Cavallo R; Giachino O
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S67-71. PubMed ID: 18799057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF alpha agents in vasculitis].
    Solans Laqué R; Bosch Gil JA
    Med Clin (Barc); 2008 Feb; 130(3):93-4. PubMed ID: 18261379
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of primary systemic vasculitis with TNF alpha-antagonists].
    Gause A; Arbach O; Lamprecht P
    Z Rheumatol; 2003 Jun; 62(3):228-34. PubMed ID: 12827398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis.
    Silva F; Cisternas M; Specks U
    Curr Rheumatol Rep; 2012 Dec; 14(6):501-8. PubMed ID: 22956157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P
    J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.
    Gómez-Puerta JA; Hernández-Rodríguez J; López-Soto A; Bosch X
    Chest; 2009 Oct; 136(4):1101-1111. PubMed ID: 19809051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New aspects in ANCA-associated vasculitides].
    Lamprecht P
    Med Klin (Munich); 2004 Sep; 99(9):518-22. PubMed ID: 15372181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
    Clain JM; Specks U
    Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.
    Booth AD; Jayne DR; Kharbanda RK; McEniery CM; Mackenzie IS; Brown J; Wilkinson IB
    Circulation; 2004 Apr; 109(14):1718-23. PubMed ID: 15037536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
    Mukhtyar C; Luqmani R
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv31-6. PubMed ID: 16239383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting B lymphocytes as therapy for ANCA-associated vasculitis.
    Golbin JM; Specks U
    Rheum Dis Clin North Am; 2007 Nov; 33(4):741-54, v. PubMed ID: 18037114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S3. Rituximab for ANCA-associated vasculitides: the French experience.
    Charles P; Guillevin L
    Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Lee RW; D'Cruz DP
    Drugs; 2008; 68(6):747-70. PubMed ID: 18416584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
    Miloslavsky EM; Lu N; Unizony S; Choi HK; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Fervenza F; Monach PA; Specks U; Stone JH
    Arthritis Rheumatol; 2016 Dec; 68(12):2945-2952. PubMed ID: 27428559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.